Your browser doesn't support javascript.
loading
Research progress of pyruvate kinase type M2 in hepatocellular carcinoma / 中华肝脏病杂志
Chinese Journal of Hepatology ; (12): 117-120, 2022.
Article in Chinese | WPRIM | ID: wpr-935921
ABSTRACT
Primary hepatocellular carcinoma is one of the most common high-grade malignant tumors in the world. Its incidence ranks fifth among malignant tumors in China, and various therapeutic measures have poor curative effect. Pyruvate kinase type M2 is a key enzyme in the glycolytic pathway, and its abnormal expression in liver cancer is closely related to the proliferation, metastasis, diagnosis, treatment, prognosis, as well as drug and radiation resistance. Therefore, multi-pathway targeted regulation of pyruvate kinase type M2 use is expected to become a new direction for the treatment of primary liver cancer.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Prognosis / Pyruvate Kinase / China / Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Prognostic study Limits: Humans Country/Region as subject: Asia Language: Chinese Journal: Chinese Journal of Hepatology Year: 2022 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Prognosis / Pyruvate Kinase / China / Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Prognostic study Limits: Humans Country/Region as subject: Asia Language: Chinese Journal: Chinese Journal of Hepatology Year: 2022 Type: Article